ArticleCureus2026
External Validation of PathFx 3.0 Model on a Single-Centre Portuguese Population.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose PathFx 3.0 (Jonathan A. Forsberg, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Rikard Wedin, Karolinska Institutet, Stockholm, Sweden) is a prognostic model designed to predict survival in patients with bone metastatic disease. While it has been widely validated, concerns remain regarding its application across different healthcare systems. This study aimed to externally validate the performance of PathFx 3.0 in a Portuguese cohort. Methods A retrospective cohort of patients who underwent surgery for skeletal metastases between January 2018 and April 2023 was analysed. Survival probabilities at one, three, six, 12 and 24 months were generated for each patient. Performance was assessed using the area under the receiver operating characteristic curve (AUC-ROC) with 95% confidence intervals, Brier scores and calibration. Results A total of 49 patients were included, with a median follow-up of 19 months (interquartile range (IQR) 5-35). Observed survival was 89.8% at one month, 81.6% at three months, 69.4% at six months, 65.3% at 12 months and 42.9% at 24 months. Discrimination was poor at one month (area under the curve (AUC) 0.495) but improved in subsequent time periods, with AUC values of 0.760 at three months, 0.773 at six months, 0.791 at 12 months and 0.752 at 24 months. Brier scores ranged from 0.172 to 0.246. Calibration analysis showed good agreement between predicted and observed outcomes, except in the early post-operative period. Conclusion PathFx 3.0 demonstrated good performance in the studied population. While early survival prediction remains limited, the model provides valuable prognostic support for operative decision-making in patients with metastatic bone disease in later time periods. Continued external validation in larger, multicentric Portuguese cohorts is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.